WINTON GROUP Ltd Decreases Stock Holdings in ADMA Biologics Inc $ADMA

WINTON GROUP Ltd reduced its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 74.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 70,531 shares of the biotechnology company’s stock after selling 202,286 shares during the quarter. WINTON GROUP Ltd’s holdings in ADMA Biologics were worth $1,034,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Westfield Capital Management Co. LP bought a new position in ADMA Biologics in the 3rd quarter valued at $74,866,000. Thrivent Financial for Lutherans increased its position in shares of ADMA Biologics by 78.1% during the 2nd quarter. Thrivent Financial for Lutherans now owns 3,315,425 shares of the biotechnology company’s stock valued at $60,373,000 after purchasing an additional 1,453,924 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of ADMA Biologics by 66.4% during the 2nd quarter. Franklin Resources Inc. now owns 2,719,016 shares of the biotechnology company’s stock worth $49,513,000 after purchasing an additional 1,085,286 shares during the period. First Light Asset Management LLC bought a new stake in shares of ADMA Biologics during the 2nd quarter worth $17,338,000. Finally, Ranger Investment Management L.P. boosted its holdings in shares of ADMA Biologics by 49.1% in the 2nd quarter. Ranger Investment Management L.P. now owns 2,390,375 shares of the biotechnology company’s stock worth $43,529,000 after buying an additional 786,865 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

ADMA has been the subject of several research reports. Zacks Research upgraded shares of ADMA Biologics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of ADMA Biologics in a research report on Tuesday, December 23rd. Finally, Wall Street Zen raised shares of ADMA Biologics from a “hold” rating to a “buy” rating in a research report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $32.00.

ADMA Biologics Stock Performance

NASDAQ:ADMA traded up $0.06 during trading hours on Friday, reaching $15.05. The stock had a trading volume of 506,248 shares, compared to its average volume of 2,712,515. The stock has a market cap of $3.58 billion, a P/E ratio of 25.18 and a beta of 0.51. The stock has a 50 day simple moving average of $16.69 and a 200 day simple moving average of $16.72. The company has a debt-to-equity ratio of 0.16, a quick ratio of 3.74 and a current ratio of 6.71. ADMA Biologics Inc has a 12-month low of $13.76 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $0.20 EPS for the quarter, meeting analysts’ consensus estimates of $0.20. The firm had revenue of $139.16 million for the quarter, compared to analysts’ expectations of $139.80 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The business’s revenue for the quarter was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.46 EPS. On average, research analysts forecast that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

Insider Transactions at ADMA Biologics

In related news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of the business’s stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the sale, the chief operating officer directly owned 466,600 shares in the company, valued at approximately $7,292,958. The trade was a 2.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Steve Elms acquired 7,000 shares of the company’s stock in a transaction on Thursday, March 5th. The shares were acquired at an average cost of $15.67 per share, for a total transaction of $109,690.00. Following the completion of the acquisition, the director owned 2,038,730 shares of the company’s stock, valued at approximately $31,946,899.10. The trade was a 0.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 3.50% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.